PDS Biotech publishes Phase 2 trial results for HPV16 treatment.
PDS Biotech announced publication of VERSATILE-002 results showing 39.3 months median overall survival, beating published benchmarks for HPV16-positive Head and Neck Cancer.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed